O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Tsipi Keren Lehrer Compugen R&D Grants Strategy

726 visualizações

Publicada em

Financing Early Stage Ventures
Wednesday, February 20, 2008

Publicada em: Educação, Negócios
  • You can hardly find a student who enjoys writing a college papers. Among all the other tasks they get assigned in college, writing essays is one of the most difficult assignments. Fortunately for students, there are many offers nowadays which help to make this process easier. The best service which can help you is ⇒ www.HelpWriting.net ⇐
       Responder 
    Tem certeza que deseja  Sim  Não
    Insira sua mensagem aqui
  • A professional Paper writing services can alleviate your stress in writing a successful paper and take the pressure off you to hand it in on time. Check out, please ⇒ www.WritePaper.info ⇐
       Responder 
    Tem certeza que deseja  Sim  Não
    Insira sua mensagem aqui
  • Seja a primeira pessoa a gostar disto

Tsipi Keren Lehrer Compugen R&D Grants Strategy

  1. 1. Compugen R&D Grants Strategy MIT Forum meeting Tsipi Keren-Lehrer February 20th 2008
  2. 2. Agenda • Compugen in a nutshell • Grants Strategy in Compugen • Summary 2
  3. 3. Compugen • Established as an Incubator company (1993) • Traded on NASDAQ and TASE • Based in Tel Aviv • 75 employees, mainly R&D – Unique team of biologists, computer scientists, mathematicians, MDs • Affiliate - Evogene (TASE - EVGN) – Compugen model in Ag-bio 3
  4. 4. Compugen’s Business Model • Develop innovative predictive models • Build specific discovery engines • Discover in-silico • Validate experimentally • Out-license for further development – Diagnostic biomarkers – Therapeutic candidates – Drug targets – Research capabilities • Revenues from milestones and royalties 4
  5. 5. Agenda • Compugen in a nutshell • Grants Strategy in Compugen • Summary 5
  6. 6. Taking Grants - Why? • Share the research risk • Biotech companies live from investments & grants… “Although about 340 biotech companies have their shares listed on major US stock exchanges, the vast majority of these firms are money losers*” *Standard & Poor’s Industry Surveys, Biotechnology, June 2005 6
  7. 7. Grants recognized in financial reports 7
  8. 8. General Grants Strategy • Stick to Compugen’s R&D roadmap – Don’t fit your R&D for a grant • Prefer at least $200K grant request – Effort is needed for preparations & reports • Carefully select your grant source • Carefully select your partner/s • We will be happy to return the money back… 8
  9. 9. OCS – Israeli Chief Scientist • R&D grants – Yearly applications • Magnets – Compugen participated in 3 consortia • Da’at, 1998-2002 • Tevel, 2000-2005 • Pharmalogica, 2002-2004 • Magneton 9
  10. 10. Trends in OCS • Higher competition – Lowering budget – Change in the law Knowledge transfer is OK more applications • Policy trend: less money to more companies – Approval rate currently 60-80% approved projects – Support rate • Policy change: 50% 20-50% support today • Actual average: 34% 17.4% of a project is funded • Biotechnology became a preferred area – 2% in 2002 23% in 2005 (of total budget) 10
  11. 11. OCS - An Important Grant Source • To take or not to take…? • Secure commercialization potential – State business model beforehand – Manufacturing – Out-licensing IP 11
  12. 12. EC FP6 Projects • SIMAP MAP-Kinase pathway model (Human) $3.8M – Compugen’s share for 3 years about 25% – We are the coordinator (1st time) • RIBOSYS pre-mRNA metabolism model (Yeast) $2.8M – Compugen’s share for 3 years less than 20% 12
  13. 13. EC FP6/FP7 - Many Advantages Favors SME 75% support R&D law limitations does not apply No return!!! Long funding assurance Future grants (... ) It’s not just the money… Free resources (e.g. data, validation) New collaborations; Strategic partners Industrial intelligence Market access 13
  14. 14. However… Long & VERY bureaucratic process (~1Y) Long-term commitment (min 3Y) Contractual complexity (collaborators>1) IP / Technology access Potential legal conflicts 14
  15. 15. Other Grants • Bi-National • Agreements / funds (e.g. BIRD) / Multi-national companies (e.g. Merck) • OCS budget • More focus on the late stages of the project • Private foundations • General / per disease • Only few of them fund foreign for-profit 15
  16. 16. Agenda • Compugen in a nutshell • Grants Strategy in Compugen • Summary 16
  17. 17. Summary • Many grant sources • Carefully select your source / partner • Keep original business model • Could be crucial for the company 17
  18. 18. Thank You Tsipi Keren-Lehrer tsipikl@compugen.co.il

×